LIN Linde plc

Q3 2025 10-Q

Filed: Oct 31, 2025Period ending Sep 30, 2025

Health Care

Industrial Inorganic ChemicalsSEC EDGAR

Linde plc (LIN) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 31, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• Revenue $8,615M Q3 2025, up 3% YoY from $8,356M Q3 2024; nine months $25,222M vs $24,723M, up 2%
• Reported operating margin 27.5% Q3 2025 vs 25.0% Q3 2024; adjusted margin 29.7% vs 29.6% YoY Q3

+3 more insights

Risk Factors

• No material changes to risk factors from 2024 10-K for fiscal 2025 quarter
• Carried-forward regulatory risk: compliance with evolving environmental laws impacting operations

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$8.6B

▲ +3.1% YoY▲ +1.4% QoQ

Net Income

$1.9B

▲ +24.5% YoY▲ +9.2% QoQ

Operating Margin

27.5%

▲ +251bp YoY▼ -24bp QoQ

Net Margin

22.4%

▲ +384bp YoY▲ +160bp QoQ

ROE

5.0%

Total Assets

$86.0B

EPS (Diluted)

$4.10

▲ +26.9% YoY▲ +9.9% QoQ

Operating Cash Flow

$2.9B

▲ +7.9% YoY▲ +33.3% QoQ

Source: XBRL data from Linde plc Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Linde plc

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.